5 assets in Cerebral Arteriopathy, Autosomal Dominant, With Subcortical Infarcts And Leukoencephalopathy, Type 1

Therapeutic assets addressing Cerebral Arteriopathy, Autosomal Dominant, With Subcortical Infarcts And Leukoencephalopathy, Type 1, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Adrenomedullin Cerebral Arteriopathy, Autosomal Dominant, With Subcortical Infarcts And Leukoencephalopathy, Type 1	National Cerebral and Cardiovascular Center, Japan	P2	B (57)
Cerebrolysin Cerebral Arteriopathy, Autosomal Dominant, With Subcortical Infarcts And Leukoencephalopathy, Type 1	Ever Neuro Pharma GmbH	P2	CCC (53)
Fremanezumab Cerebral Arteriopathy, Autosomal Dominant, With Subcortical Infarcts And Leukoencephalopathy, Type 1	Mayo Clinic	P2	CCC (53)
Physiologic Sodium Chloride Solution Cerebral Arteriopathy, Autosomal Dominant, With Subcortical Infarcts And Leukoencephalopathy, Type 1	Ever Neuro Pharma GmbH	P2	CCC (53)
Cilostazol Cerebral Arteriopathy, Autosomal Dominant, With Subcortical Infarcts And Leukoencephalopathy, Type 1	Mayo Clinic	P1/2	CCC (48)